Stem cell therapy for pulmonary arterial hypertension: An update.
Stem cell therapy for pulmonary arterial hypertension: An update.
复制标题
肺动脉高压的干细胞治疗：最新进展。
DOI：
10.1016/j.healun.2022.02.020
复制
发表时间：
2022-06
影响因子：
8.9
通讯作者：
Sun, Zhongjie
中科院分区：
文献类型：
--
作者：
Sun, Qiwei Wilton;Sun, Zhongjie
关键词：
肺动脉高压（PAH）仍然是一种致命的疾病，目前尚无法治愈这种危及生命的医学问题。 PAH 诊断后的平均寿命约为 5-7 年。因此，迫切需要在概念上进行突破，开发新的 PAH 治疗策略。越来越多的证据表明，干细胞正在成为一种新型有效的治疗方法，但对其潜在机制的了解仍然有限。本综述重点介绍了干细胞成功逆转 PAH 患者和 PAH 研究中使用的常见啮齿动物模型的肺血管内皮功能障碍、肺动脉平滑肌细胞 (PASMC) 过度增殖和线粒体功能障碍的机制。它们可以调节 PAH 中涉及的常见潜在途径，包括一氧化氮合酶 (eNOS)、线粒体调节因子、microRNA 和 STAT3-BMPR 信号传导。基因修饰进一步增强干细胞对PAH的治疗效果。临床试验显示间充质干细胞和内皮祖细胞对 PAH 具有良好的治疗潜力。还讨论了潜在的限制和挑战。目前的研究结果支持需要进一步研究和验证干细胞疗法治疗肺动脉高压。干细胞疗法对于治疗肺血管功能障碍、肺动脉高压和右心室衰竭具有广阔的前景。
Pulmonary arterial hypertension (PAH) remains a deadly disease, and there currently is no cure for this life-threating medical problem. The average lifespan is about 5–7 years after diagnosis of PAH. Therefore, a conceptual breakthrough to develop new therapeutic strategies for PAH is urgently needed. Growing evidence shows that stem cells are emerging as a novel effective treatment, but the understanding of its underlying mechanisms is still limited. This review highlights the mechanisms through which stem cells successfully reverse pulmonary vascular endothelial dysfunction, pulmonary artery smooth muscle cell (PASMC) over-proliferation, and mitochondrial dysfunction in PAH patients and common rodent models used in PAH research. They can modulate common underlying pathways involved in PAH, including the nitric oxide synthase (eNOS), mitochondrial regulators, microRNAs and STAT3-BMPR signaling. Genetic modifications further enhance the therapeutic effects of stem cells on PAH. Clinical trials showed promising therapeutic potential of mesenchymal stem cells and endothelial progenitor cells for PAH. Potential limitations and challenges are also discussed. The current findings support the need for further investigation and validation of stem cell therapy for PAH. Stem cell therapy holds a great promise for pulmonary vascular dysfunction, pulmonary arterial hypertension and right ventricular failure.
登录
查看更多内容
影响因子：
56.9
作者：
Asahara, T;Murohara, T;Isner, JM
通讯作者：
Isner, JM
DOI：
10.1161/hypertensionaha.109.146902
发表时间：
2010-06
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Crosswhite P;Sun Z
通讯作者：
Sun Z
影响因子：
20.1
作者：
Chen K;Wang S;Sun QW;Zhang B;Ullah M;Sun Z
通讯作者：
Sun Z
DOI：
10.1161/hypertensionaha.114.03791
发表时间：
2014-11
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Crosswhite P;Chen K;Sun Z
通讯作者：
Sun Z
影响因子：
16
作者：
Feng, Rui;Ullah, Mujib;Sun, Zhongjie
通讯作者：
Sun, Zhongjie